191 related articles for article (PubMed ID: 35395864)
1. A proteolysis-targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growth.
Li X; Yao Y; Wu F; Song Y
J Hematol Oncol; 2022 Apr; 15(1):41. PubMed ID: 35395864
[TBL] [Abstract][Full Text] [Related]
2. Small-molecule inhibitor of AF9/ENL-DOT1L/AF4/AFF4 interactions suppresses malignant gene expression and tumor growth.
Wu F; Nie S; Yao Y; Huo T; Li X; Wu X; Zhao J; Lin YL; Zhang Y; Mo Q; Song Y
Theranostics; 2021; 11(17):8172-8184. PubMed ID: 34373735
[TBL] [Abstract][Full Text] [Related]
3. Structure, function and inhibition of critical protein-protein interactions involving mixed lineage leukemia 1 and its fusion oncoproteins.
Li X; Song Y
J Hematol Oncol; 2021 Apr; 14(1):56. PubMed ID: 33823889
[TBL] [Abstract][Full Text] [Related]
4. Transcription control by the ENL YEATS domain in acute leukaemia.
Erb MA; Scott TG; Li BE; Xie H; Paulk J; Seo HS; Souza A; Roberts JM; Dastjerdi S; Buckley DL; Sanjana NE; Shalem O; Nabet B; Zeid R; Offei-Addo NK; Dhe-Paganon S; Zhang F; Orkin SH; Winter GE; Bradner JE
Nature; 2017 Mar; 543(7644):270-274. PubMed ID: 28241139
[TBL] [Abstract][Full Text] [Related]
5. Human Polymerase-Associated Factor complex (PAFc) connects the Super Elongation Complex (SEC) to RNA polymerase II on chromatin.
He N; Chan CK; Sobhian B; Chou S; Xue Y; Liu M; Alber T; Benkirane M; Zhou Q
Proc Natl Acad Sci U S A; 2011 Sep; 108(36):E636-45. PubMed ID: 21873227
[TBL] [Abstract][Full Text] [Related]
6. The Intrinsically Disordered Proteins MLLT3 (AF9) and MLLT1 (ENL) - Multimodal Transcriptional Switches With Roles in Normal Hematopoiesis, MLL Fusion Leukemia, and Kidney Cancer.
Kabra A; Bushweller J
J Mol Biol; 2022 Jan; 434(1):167117. PubMed ID: 34174329
[TBL] [Abstract][Full Text] [Related]
7. Targeting recruitment of disruptor of telomeric silencing 1-like (DOT1L): characterizing the interactions between DOT1L and mixed lineage leukemia (MLL) fusion proteins.
Shen C; Jo SY; Liao C; Hess JL; Nikolovska-Coleska Z
J Biol Chem; 2013 Oct; 288(42):30585-30596. PubMed ID: 23996074
[TBL] [Abstract][Full Text] [Related]
8. Collaboration of MLLT1/ENL, Polycomb and ATM for transcription and genome integrity.
Ui A; Yasui A
Nucleus; 2016 Apr; 7(2):138-45. PubMed ID: 27310306
[TBL] [Abstract][Full Text] [Related]
9. Cooperative gene activation by AF4 and DOT1L drives MLL-rearranged leukemia.
Okuda H; Stanojevic B; Kanai A; Kawamura T; Takahashi S; Matsui H; Takaori-Kondo A; Yokoyama A
J Clin Invest; 2017 May; 127(5):1918-1931. PubMed ID: 28394257
[TBL] [Abstract][Full Text] [Related]
10. ENL links histone acetylation to oncogenic gene expression in acute myeloid leukaemia.
Wan L; Wen H; Li Y; Lyu J; Xi Y; Hoshii T; Joseph JK; Wang X; Loh YE; Erb MA; Souza AL; Bradner JE; Shen L; Li W; Li H; Allis CD; Armstrong SA; Shi X
Nature; 2017 Mar; 543(7644):265-269. PubMed ID: 28241141
[TBL] [Abstract][Full Text] [Related]
11. Discovery, Structure-Activity Relationship and In Vitro Anticancer Activity of Small-Molecule Inhibitors of the Protein-Protein Interactions between AF9/ENL and AF4 or DOT1L.
Li X; Wu X; Nie S; Zhao J; Yao Y; Wu F; Mishra CB; Ashraf-Uz-Zaman M; Moku BK; Song Y
Cancers (Basel); 2023 Nov; 15(21):. PubMed ID: 37958457
[TBL] [Abstract][Full Text] [Related]
12. Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
Chen WL; Li DD; Chen X; Wang YZ; Xu JJ; Jiang ZY; You QD; Guo XK
Eur J Med Chem; 2020 Feb; 188():112027. PubMed ID: 31923859
[TBL] [Abstract][Full Text] [Related]
13. Hematopoietic transformation in the absence of MLL1/KMT2A: distinctions in target gene reactivation.
Chen Y; Ernst P
Cell Cycle; 2019 Jul; 18(14):1525-1531. PubMed ID: 31161857
[TBL] [Abstract][Full Text] [Related]
14. An AF9/ENL-targted peptide with therapeutic potential in mixed lineage leukemias.
Barretto NN; Karahalios DS; You D; Hemenway CS
J Exp Ther Oncol; 2014; 10(4):293-300. PubMed ID: 25509985
[TBL] [Abstract][Full Text] [Related]
15. EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs.
Bindels EM; Havermans M; Lugthart S; Erpelinck C; Wocjtowicz E; Krivtsov AV; Rombouts E; Armstrong SA; Taskesen E; Haanstra JR; Beverloo HB; Döhner H; Hudson WA; Kersey JH; Delwel R; Kumar AR
Blood; 2012 Jun; 119(24):5838-49. PubMed ID: 22553314
[TBL] [Abstract][Full Text] [Related]
16. Distinct pathways affected by menin versus MLL1/MLL2 in MLL-rearranged acute myeloid leukemia.
Chen Y; Jones KL; Anastassiadis K; Kranz A; Stewart AF; Grembecka J; Meyerson M; Ernst P
Exp Hematol; 2019 Jan; 69():37-42. PubMed ID: 30315824
[TBL] [Abstract][Full Text] [Related]
17. Menin-MLL1 Interaction Small Molecule Inhibitors: A Potential Therapeutic Strategy for Leukemia and Cancers.
Shi Q; Xu M; Kang Z; Zhang M; Luo Y
Molecules; 2023 Mar; 28(7):. PubMed ID: 37049787
[TBL] [Abstract][Full Text] [Related]
18. An aberrantly sustained emergency granulopoiesis response accelerates postchemotherapy relapse in
Wang H; Shah CA; Hu L; Huang W; Platanias LC; Eklund EA
J Biol Chem; 2020 Jul; 295(28):9663-9675. PubMed ID: 32467231
[TBL] [Abstract][Full Text] [Related]
19. MLL-AF9 and MLL-ENL alter the dynamic association of transcriptional regulators with genes critical for leukemia.
Monroe SC; Jo SY; Sanders DS; Basrur V; Elenitoba-Johnson KS; Slany RK; Hess JL
Exp Hematol; 2011 Jan; 39(1):77-86.e1-5. PubMed ID: 20854876
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a Selective Inhibitor for the YEATS Domains of ENL/AF9.
Christott T; Bennett J; Coxon C; Monteiro O; Giroud C; Beke V; Felce SL; Gamble V; Gileadi C; Poda G; Al-Awar R; Farnie G; Fedorov O
SLAS Discov; 2019 Feb; 24(2):133-141. PubMed ID: 30359161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]